About
Partnerships
Product Pipeline
Enabling Technologies
Resources
Contact
We envision a time when cancer
is no longer a problem
InterVenn is the cutting-edge leader for glycoprotein analysis, biomarker research, liquid-biopsy assay development, and new drug target discovery. Our unique platform uses deep learning to automate analysis of a rich field of biomarkers so diverse and complex that it would be otherwise inaccessible.
For Investors
InterVenn not only works closely with leading pharma, biotech, and diagnostic companies during every phase of development, but is also planning commercial launch of its own clinical service offerings.
For Partners
We work closely with leading pharma, biotech, and diagnostic companies during every phase of development, augmenting their systems and processes with the unique InterVenn platform.
For Physicians
Our goal has always been to help patients and their physicians by providing assays that outperform currently available ones, with a focus on cancer.
First Of Its Kind
InterVenn is building unique, powerful liquid-biopsy solutions by leveraging the rich diversity of protein glycosylation*.
Artificial Intelligence
InterVenn is decoding the glycoproteome using powerful analytics, and AI-powered software.
InterVenn’s unique, powerful liquid biopsy platform is available today.
Our solutions are suitable for a variety of studies – untargeted (discovery) and targeted (quantification), other proof-of-concept initiatives and biomarker development. Together and with a single-blood draw, we can revolutionize disease insights into opportunities for patients. Today.